Skip to main content

Advertisement

Log in

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. However, efficacy and survival for these two settings have not been compared, leaving it unclear whether these two populations can be included in the same clinical trials. Moreover, prognostic factors for patients who are recommended to receive docetaxel/pemetrexed monotherapy are largely unknown.

Methods

Docetaxel or pemetrexed was administered to 67 EGFR wild-type patients as a second-line treatment following one platinum-based combination chemotherapy and to 17 EGFR mutant patients as a third-line treatment following EGFR tyrosine kinase inhibitors and one platinum-based combination chemotherapy. Docetaxel and pemetrexed were administered at 60 and 500 mg/m2, respectively, every 3 weeks until disease progression, intolerable toxicity, or patient refusal. Overall survivals (OSs) between the two groups were compared using the log-rank test, and prognostic factors were evaluated via Cox’s proportional hazards models.

Results

The median OS was 345.5 days in the EGFR wild-type second-line group and 616 days in the EGFR mutant third-line group. Multivariate analyses revealed that the stage before first-line treatment, performance status, and EGFR status were significant prognostic factors.

Conclusions

When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta

    Google Scholar 

  2. Köhler J, Schuler M (2013) Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36:510–518

    Article  PubMed  Google Scholar 

  3. Vijayvergia N, Mehra R (2014) Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 74:437–446

    Article  CAS  PubMed  Google Scholar 

  4. Berge EM, Doebele RC (2014) Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 41:110–125

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Imielinski M, Greulich H, Kaplan B et al (2014) Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 124(4):1582–1586

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175–180

    Article  CAS  PubMed  Google Scholar 

  7. Shepherd F, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 18:2095–2103

    CAS  PubMed  Google Scholar 

  8. Fossella F, DeVore R, Kerr R et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–2362

    CAS  PubMed  Google Scholar 

  9. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    Article  CAS  PubMed  Google Scholar 

  10. Mok TS, Wu Y, Nakagawa K et al (2014) Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomized IMPRESS study. Ann Oncol 25(Supplement 5):v1–v4 (LBA2_PR)

    Google Scholar 

  11. NCCN.org. NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer version 1.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  12. The Japan Lung Cancer Society. Guidelines for the treatment of lung cancer. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3. (in Japanese)

  13. Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673

    Article  CAS  PubMed  Google Scholar 

  14. Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 15:143–155

    Article  CAS  PubMed  Google Scholar 

  15. Hanna NH, Kaiser R, Sullivan RN et al (2013) Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 31(suppl) (abstr 8034)

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Takehito Shukuya.

Ethics declarations

Conflict of interest

The authors declare no financial or personal conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shukuya, T., Ko, R., Mori, K. et al. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. Cancer Chemother Pharmacol 76, 771–776 (2015). https://doi.org/10.1007/s00280-015-2843-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2843-3

Keywords

Navigation